Madiha Derouazi
Technik-/Wissenschafts-/F&E-Leiter bei AC IMMUNE SA
Vermögen: 7 271 $ am 30.04.2024
Profil
Madiha Derouazi is the founder and current Chief Executive Officer & Director of Amal Therapeutics SA, which is founded in 2012.
She is also currently the Chief Scientific Officer at AC Immune SA, where she started in 2024.
Dr. Derouazi has a graduate degree from the Technical University of Berlin and a doctorate degree from the Swiss Federal Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AC IMMUNE SA
0,00% | 01.03.2024 | 3 175 ( 0,00% ) | 7 271 $ | 30.04.2024 |
Aktive Positionen von Madiha Derouazi
| Unternehmen | Position | Beginn |
|---|---|---|
| AC IMMUNE SA | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2024 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Gründer | 03.09.2012 |
Ehemalige bekannte Positionen von Madiha Derouazi
| Unternehmen | Position | Ende |
|---|
Ausbildung von Madiha Derouazi
| Technical University of Berlin | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
